Analysts Set Expectations for Kadmon Holdings Inc’s FY2021 Earnings (KDMN)

Kadmon Holdings Inc (NASDAQ:KDMN) – Jefferies Group issued their FY2021 EPS estimates for shares of Kadmon Holdings in a research note issued on Thursday, Zacks Investment Research reports. Jefferies Group analyst B. Amin forecasts that the company will post earnings of ($0.66) per share for the year.

Kadmon Holdings (NASDAQ:KDMN) last posted its earnings results on Wednesday, March 22nd. The company reported ($0.50) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.71) by $0.21. The business had revenue of $4.28 million for the quarter, compared to analysts’ expectations of $4.50 million.

WARNING: This article was first posted by BBNS and is owned by of BBNS. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://baseballnewssource.com/markets/jefferies-group-weighs-in-on-kadmon-holdings-incs-fy2021-earnings-kdmn-updated-updated/526023.html.

A number of other brokerages also recently weighed in on KDMN. Zacks Investment Research downgraded Kadmon Holdings from a “hold” rating to a “sell” rating in a report on Wednesday, January 4th. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of Kadmon Holdings in a report on Wednesday, February 1st. Piper Jaffray Companies reiterated an “overweight” rating and issued a $23.00 target price (down previously from $36.10) on shares of Kadmon Holdings in a report on Thursday, March 23rd. WBB Securities upgraded Kadmon Holdings from a “sell” rating to a “hold” rating and set a $3.25 target price on the stock in a report on Thursday, March 16th. Finally, Citigroup Inc dropped their target price on Kadmon Holdings from $6.00 to $4.00 and set a “neutral” rating on the stock in a report on Monday, March 27th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Kadmon Holdings currently has a consensus rating of “Buy” and an average price target of $12.14.

Kadmon Holdings (NASDAQ:KDMN) traded down 5.18% during trading on Friday, reaching $2.38. 337,373 shares of the company’s stock traded hands. Kadmon Holdings has a 12 month low of $2.36 and a 12 month high of $11.73. The stock’s market capitalization is $123.39 million. The company has a 50-day moving average of $3.32 and a 200 day moving average of $4.66.

In other news, major shareholder Daniel S. Loeb purchased 1,488,095 shares of the stock in a transaction that occurred on Monday, March 13th. The stock was acquired at an average price of $3.36 per share, with a total value of $4,999,999.20. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

Several large investors have recently made changes to their positions in KDMN. Nationwide Fund Advisors purchased a new stake in shares of Kadmon Holdings during the first quarter valued at approximately $192,000. Macquarie Group Ltd. purchased a new stake in shares of Kadmon Holdings during the fourth quarter valued at approximately $2,696,000. Perceptive Advisors LLC purchased a new stake in shares of Kadmon Holdings during the fourth quarter valued at approximately $11,821,000. State Street Corp boosted its stake in shares of Kadmon Holdings by 66.9% in the fourth quarter. State Street Corp now owns 72,514 shares of the company’s stock valued at $389,000 after buying an additional 29,076 shares during the last quarter. Finally, Goldentree Asset Management LP purchased a new stake in shares of Kadmon Holdings during the third quarter valued at approximately $1,529,000.

Kadmon Holdings Company Profile

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.

5 Day Chart for NASDAQ:KDMN

Get a free copy of the Zacks research report on Kadmon Holdings (KDMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kadmon Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc and related companies with our FREE daily email newsletter.

 

Latest News

Sources Say Luis Robert Will Be Cleared by May 20 to Sign
Sources Say Luis Robert Will Be Cleared by May 20 to Sign
Colorado Rockies Bullpen Helping Them to NL West Lead
Colorado Rockies Bullpen Helping Them to NL West Lead
Hall of Famer Given New Lease on Life
Hall of Famer Given New Lease on Life
New York Mets Have the Power
New York Mets Have the Power
Red Sox Fighting Through Illness and Injury
Red Sox Fighting Through Illness and Injury
Cleveland and Arizona Off to Fast Starts
Cleveland and Arizona Off to Fast Starts


Leave a Reply

 
© 2006-2017 BBNS.